The FDA has changed the package insert for Avastin® (bevacizumab) to include information about newly identified risks for the drug including
- Loss of ovarian function (ovarian failure).
- Bone death in the jaw (osteonecrosis).
- Bleeding and additional blood clots in patients who have already had a clot in their veins while on Avastin.
Changes to the Avastin label were announced on September 30, 2011. Read the rest of this entry »





